Biomarkers in ovarian neoplasms: opportunities, limitations, and prospects for using in reproductive-aged women


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Ovarian proliferative processes are a serious problem for reproductive-aged women. The problems in the differential diagnosis of endometriosis, ovarian tumors and neoplasms are associated with erroneous treatment and poor prognosis. The data available in global literature on achievements in noninvasive diagnosis over 2010- 2019 have been analyzed to compare the possibilities and limitations of studies of markers in biological fluids for ovarian diseases, in particular, for ovarian endometriosis.

Texto integral

Acesso é fechado

Sobre autores

S. Pavlovich

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation

Email: s_pavlovich@oparina.ru

M. Yurova

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation

Email: m_yurova@oparina4.ru

A. Melkumyan

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation

Email: dr.melkumyan@gmail.com

V. Frankevich

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation

Email: v_frankevich@oparina4.ru

V. Chagovets

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation

Email: vvchagovets@gmail.com

G. Khabas

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation

Email: g_khabas@oparina4.ru

Bibliografia

  1. Шамаракова М.В., Адамян Л.В., Асатурова А.В., Ежова Л.С., Зайцев Н.В., Юрова М.В., Мартиросян Я.О. Серомуцинозные опухоли яичников и эндометриоз у женщин репродуктивного возраста. Акушерство и гинекология. 2018; 7: 84-91. https://dx.doi.org/10.18565/ aig.2018.7.84-91
  2. Щеголев А.И., Быков А.Г., Туманова У.Н., Павлович С.В. Эндометриоз и развитие опухолей. Акушерство и гинекология. 2016; 11: 49-56. [Shchegolev A.I., Bykov A.G., Tumanova U.N., Pavlovich S.V. Endometriosis and tumorogenesis. Obstetrics and gynecology. 2016; 11: 49-56. (in Russian)]. http://dx.doi.org/10.18565/aig.2016.11.49-56
  3. Han J.Y., Lee E.J., Jee B.C., Kim S.H. Menstrual characteristics in Korean women with endometriosis: a pilot study. Obstet Gynecol Sci. 2017; 61(1): 142146. doi: 10.5468/ogs.2018.61.1.142
  4. Rogers P.A.W., D’Hooghe T. M., Fazleabas A., et al. Defining future directions for endometriosis research: workshop report from the 2011 World Congress of Endometriosis in Montpellier, France. Reprod Sci. 2013; 20(5): 483-99. doi: 10.1177/1933719113477495
  5. Nisenblat V., Bossuyt P.M.M., Shaikh R., Arora D., Farquhar C., Jordan V., et al. Blood biomarkers for the noninvasive diagnosis of endometriosis. Cochrane Database Syst Rev. 2016; (5): CD012179. doi:https:// doi.org/10.1002/ 14651858.
  6. Da Silva C. M., Vilaga Belo A., Passos Andrade S., Peixoto Campos P., Cristina Franga Ferreira M., Lopes da Silva-Filho A., et al. Identification of local angiogenic and inflammatory markers in the menstrual blood of women with endometriosis. Biomedicine & Pharmacotherapy. 2014; 68(7): 899-904. doi: 10.1016/j.biopha.2014.08.005
  7. Yang H., Zhou B., Prinz M., Siegel D. Proteomic analysis of menstrual blood. Mol Cell Proteomics. 2012; 11(10): 1024-35. doi: 10.1074/mcp.M112.018390
  8. Ueland F.R., Li A.J. Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum. UpToDate. Reviewed. 2019; 8(5): 55.
  9. Cho, S., Mutlu, L., Grechukhina, O., Taylor, H. SCirculating microRNAs as potential biomarkers for endometriosis. Fertil Steril. 2015; 103(5): 1252-60.e1. doi: 10.1016/j.fertnstert.2015.02.013.
  10. May K.E., Conduit-Hulbert S.A., Villar J., Kirtley S., Kennedy S.H., Becker C.M. Peripheral biomarkers of endometriosis: a systematic review. Hum Reprod Update. 2010;16: 651-74. doi: 10.1093/humupd/dmq009.
  11. Liu E., Nisenblat V., Farquhar C., Fraser I., Bossuyt P.M.M., Johnson N., et al. Urinary biomarkers for the noninvasive diagnosis of endometriosis. Cochrane Database Syst Rev. 2015; (12):CD012019. doi: https:// doi. org/10.1002/14651858.
  12. Vodolazkaia A., El-Aalamat Y., Popovic D., Mihalyi A., Bossuyt, X., Kyama C.M., et al. Evaluation of a panel of 28 biomarkers for the non-invasive diagnosis of endometriosis. Human Reproduction, 2012; 27(9), 2698-2711. doi:10.1093/ humrep/des234
  13. Vicente-Munoz S., Morcillo I., Puchades-Carrasco L., Paya V., Pellicer A., Pineda-Lucena A. Nuclear magnetic resonance metabolomic profiling of urine provides a noninvasive alternative to the identification of biomarkers associated with endometriosis. Fertil Steril. 2015; 104(5): 1202-9. doi:10.1016/j. fertnstert.2015.07.1149
  14. Gjavotchanoff R. CYFRA 21-1 in urine: a diagnostic marker for endometriosis? Int J. Womens Health. 2015; 7: 205-11. doi: 10.2147/ IJWH.S75288
  15. Wang L., Liu H. Y., Shi H. H., Lang J. H., Sun W. Urine peptide patterns for non-invasive diagnosis of endometriosis: a preliminary prospective study. Eur J. Obst Gyn Repr Biol. 2014; 177: 23-28. doi: 10.1016/j.ejogrb.2014.03.011
  16. Simonelli A., Guadagni R., De Franciscis P., Colacurci N., Pieri M., Basilicata P., et al. Environmental and occupational exposure to bisphenol A and endometriosis: urinary and peritoneal fluid concentration levels. International Archives of Occupational and Environmental Health. 2016; 90(1): 49-61. doi:10.1007/ s00420-016-1171-1.
  17. Rahmioglu N., Fassbender A., Vitonis A.F., et al. World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project: III. Fluid biospecimen collection, processing, and storage in endometriosis research. Fertil Steril. 2014; 102(5): 1233-43.
  18. Guerriero S., Condous G., Alcazar J.L., et al. How to Perform Ultrasonography in Endometriosis. Springer International Publishing AG, 2018. https://doi. org/10.1007/978-3-319-71138-6.
  19. Адамян Л.В., Азнаурова Я.Б. Биомаркеры эндометриоза - современные тенденции. Проблемы репродукции. 2018; 24(1): 57-62. [Adamyan L.V., Aznaurova Ya.B. Biomarkers of endometriosis - current trends. Reproduction problems. 2018; 24(1): 57-62. (in Russ.)]. https://doi.org/10.17116/ repro201824157-62
  20. Dodge J.E., Covens A.L., Lacchetti C., Elit L.M., Le T., Devries-Aboud M., Fung-Kee-Fung M. Preoperative identification of a suspicious adnexal mass: A systematic review and meta-analysis. Gyn Oncol. 2012; 126(1): 157-66. doi: 10.1016/j.ygyno.2012.03.048
  21. Li Q.K., Shah P., Tian Y., et al. An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors. Clin Proteomics. 2017; 14: 16. doi:10.1186/ s12014-017-9152-2
  22. Jacobs I.J., Menon U., Ryan A., Gentry-Maharaj A., Burnell M., Kalsi J.K., et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016; 389(10022): 945-56.
  23. Nezhat F.R., Apostol R., Nezhat C., Pejovic T. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. Am J. Obstet Gynecol. 2015; 213(3): 262-7. doi: 10.1016/j.ajog.2015.03.044
  24. Soletormos G., Dufy M.J., Othman Abu Hassan S., Verheijen R.H., Tholander B., Bast R.C. Jr, Gaarenstroom K.N., Sturgeon C.M., Bonfrer J.M., Petersen P.H., Troonen H., CarloTorre G., Kanty Kulpa J., Tuxen M.K., Molina R. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the european group on tumor markers. Int J. Gynecol Cancer. 2016; 26: 43-51. doi: 10.1097/IGC.0000000000000586
  25. Fassbender A., Burney R.O., O. D.F., D’Hooghe T., Giudice L. Update on Biomarkers for the Detection of Endometriosis. Biomed Res Int. 2015; 2015: 130854. doi: 10.1155/2015/130854
  26. Luisi S.L., et al. Serum markers for the noninvasive diagnosis of endometriosis. Women’s Heal. 2015; 11(5): 603-10. doi: 10.2217/whe.15.46
  27. Zhang Z., Bast R.C., Yu Y.H., Li J.N., Sokoll L.J., Rai A.J., Rosenzweig J.M., Cameron B., Wang Y.Y., Meng X.Y., Berchuck A., van Haaften-Day C., Hacker N.F., de Bruijn H.W.A., van der Zee A.G.J., Jacobs I.J., Fung E.T., Chan D.W. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Can Res. 2004;64(16):5882-5890. doi: 10.1158/0008-5472.CAN-04-0746
  28. Kurdoglu Z., Gursoy R., Kurdoglu M., Erdem M., Erdem O., Erdem A. Comparison of the clinical value of CA 19-9 versus CA 125 for the diagnosis of endometriosis. Fertil Steril. 2009; 92(5): 1761-63. doi: 10.1016/j.fertnstert.2009.05.022
  29. Tuten A., Kucur M., Imamoglu M., Kay a B., Acikgoz A. S., Yilmaz N., et al. Copeptin is associated with the severity of endometriosis. Archives of Gynecology and Obstetrics. 2014; 290(1): 75-82. doi: 10.1007/s00404-014-3163-2
  30. Shetty V., Hafner J., Shah P., Nickens Z., Philip R. Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics. Clin Proteomics. 2012; 9(1): 10. doi: 10.1186/ 1559-0275-9-10.
  31. Kuzmanov U., Musrap N., Kosanam H., Smith C.R., Batruch I., Dimitromanolakis A., Diamandis E.P. Glycoproteomic identifcation of potential glycoprotein biomarkers in ovarian cancer proximal fuids. Clin Chem Lab Med. 2013; 51(7): 1467-76. doi: 10.1515/cclm-2012-0642.
  32. Nikolova T., Zivadinovic R., Evtimovska N., Klisarovska V., Stanojevic M., Georgievska J. et al. Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women. J. Obst Gyn Res. 2017; 43(12): 1870-79. doi:10.1111/ jog.13466
  33. Kim B., Park Y., Kim B., Ahn H.J., Lee K.-A., Chung J.E., Han S.W. Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer. Journal of Clinical Laboratory Analysis. 2018; e22624. doi: 10.1002/jcla.22624
  34. Practice Bulletin No. 174. Obst Gyn. 2016; 128(5): e210-e226. doi:10.1097/ aog.0000000000001768
  35. Li J., Wang X., Qu W., Wang J., Jiang S. Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis. Clinica Chimica Acta, 2018. 488. doi: 10.1016/j.cca.2018.11.011
  36. Al Musalhi K., Al Kindi M., Al Aisary F., et al. Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass. Oman Med J. 2016; 31(5): 336-344. doi:10.5001/ omj.2016.68
  37. MariAlexandre J., BarcelyMolina M., OlcinaGuillem M., Garcia-Oms J., BrazaBonls A., GilabertEstelles J. MicroRNAs: New players in endometriosis. World J. Obstet Gynecol. 2016; 5(1): 28-38. doi.org/10.5317/ wjog.v5.i1.28
  38. Braza Bonls A., Mari Alexandre J., Gilabert Estelles J., S6nchez Izquierdo D., Espaca F., Estelles A., Gilabert Estelles J. MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors. Hum Reprod. 2014; 29: 97888. doi: 10.1093/humrep/ deu019.
  39. Zhao Y., Li C., Wang M., Su L., Qu Y., Li J., Yu B., Yan M., Yu Y., Liu B., Zhu Z. Decrease of miR2023p expression, a novel tumor suppressor, in gastric cancer. PLoS One 2013; 8: e69756. PMID: 23936094 doi: 10.1371/journal. pone.0069756
  40. Laudanski P., Charkiewicz R., Kuzmicki M., Szamatowicz J., Charkiewicz A., Niklinski J. MicroRNAs expression profiling of eutopic proliferative endometrium in women with ovarian endometriosis. Reprod Biol Endocrinol. 2013; 11: 78. doi: 10.1186/147778271178
  41. Kozomara А., Birgaoanu M., Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Research. 2019; 47(D1): D155-D162. https://doi.org/10.1093/nar/gky114
  42. Creed J., Maggrah A., Reguly B., Harbottle A. Mitochondrial DNA deletions accurately detect endometriosis in symptomatic females of child-bearing age. Biomark Med. 2019; 13(4): 291-306. doi: 10.2217/ bmm-2018-0419
  43. Liu T., Huang Y., Zhang J., et al. Transplantation of human menstrual blood stem cells to treat premature ovarian failure in mouse model. Stem Cells Dev. 2014; 23(13):1548-1557. doi: 10.1089/scd.2013.0371
  44. Lin J., Xiang D., Zhang J.L., Allickson J., Xiang C. Plasticity of human menstrual blood stem cells derived from the endometrium. J. Zhejiang Univ Sci B. 2011;12(5): 372-380. doi: 10.1631/jzus.B1100015
  45. Qin W., Xiong Y., Chen J., Huang Y., Liu T. DC-CIK cells derived from ovarian cancer patient menstrual blood activate the TNFR1-ASK1-AIP1 pathway to kill autologous ovarian cancer stem cells. J. Cell Mol Med. 2018; 22(7): 3364-76. doi: 10.1111/jcmm.13611
  46. Шварёв Е.Г., Дикарёва Л.В., Оводенко Д.Л., Аюпова А.К., Шварёв Г.Е. Маркеры эндометриальных биологических жидкостей в диагностике опухолей придатков матки. Опухоли женской репродуктивной системы. 2015; 11(4): 76-80. doi: 10.17650/1994-4098-2015-114-76-80
  47. Володин М.А., Шварёв Е.Г., Бохман Я.В., Сафронникова Н.Р. Способ диагностики аденокарциномы эндометрия. Патент на изобретение. 1987.
  48. Shimizu K., Kama da Y., Sakamoto A., Matsuda M., Nakatsuka M., Hiramatsu Y. High Expression of High-Mobility Group Box 1 in Menstrual Blood: Implications for Endometriosis. Reprod Sci. 2017; 24(11):1532-7. doi: 10.1177/1933719117692042
  49. Борисова А.В., Чаговец В.В., Козаченко А.В., Стародубцева Н.Л., Кононихин А.С., Салимова Д.Ф., Коган Е.А., Адамян Л.В., Франкевич В.Е., Сухих Г.Т. Сравнительный анализ липидного состава перитонеальной жидкости и плазмы крови у пациенток с наружным генитальным эндометриозом и миомой матки. Акушерство и гинекология. 2017; 6: 74-82. http://dx.doi.org/10.18565/aig.2017.6.74-82
  50. Sans M., Gharpure K., Tibshirani R., Zhang J., Liang L., Liu J., et al. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Research. 2017); 77(11): 2903-13. doi: 10.1158/0008-5472
  51. Delcourt V., Franck J., Leblanc E., Narducci F., Robin Y.-M., Gimeno J.-P., et al. Combined Mass Spectrometry Imaging and Top-down Microproteomics Reveals Evidence of a Hidden Proteome in Ovarian Cancer. EBioMedicine. 2017; 21: 55-64. doi: 10.1016/j.ebiom.2017.06.001
  52. D’Hooghe T.M., ed. Biomarkers for Endometriosis. State of the Art. Springer International Publishing AG,2017; 227-258. ISBN 978-3-319-59856-7. doi: 10.1007/978-3-319-59856-7_12
  53. Wolrab D., et al. Oncolipidomics: Mass spectrometric quantitation of lipids in cancer research, Trends in AnalyticalChemistry,2019; 120: 115480. https://doi.org/10.1016/j.trac.2019.04.012
  54. Yan F., Zhao H., Zeng Y. Lipidomics : a promising cancer biomarker. Clin Trans Med. 2018; 7: 21. https://doi.org/10.1186/s40169-018-0199-0
  55. Liu X. Quantitative evaluation of a high resolution lipidomics platform. 2019. doi: https://doi.org/10.1101/627687
  56. Braicu E.I., et al. High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism. Oncotarget. 2017; 8(61):102912-102922. doi: 10.18632/oncotarget.22076
  57. Haznadar M. (ed.), Analysis L., Tissues T. Cancer Metabolism: Methods and Protocols, Methods in Molecular Biology.2019; Chapter 11:1928. https://doi.org/10.1007/978-1-4939-9027-6_11
  58. Patti G.J., Yanes O., Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol. 2012; 13(4): 263-9. doi: 10.1038/nrm3314
  59. Vouk K., Hevir N., Ribic-Pucelj M., Haarpaintner G., Scherb H., Osredkar J., et al. Discovery of phosphatidylcholines and sphingomyelins as biomarkers for ovarian endometriosis. Hum Reprod. 2012; 27(10): 2955-65. doi: 10.1093/humrep/des152
  60. Adamyan L.V., Starodubtseva N., Borisova A., Stepanian A.A., Chagovets V., Salim ova D., Wang Z., Kononikhin A., Popov I., Bugrova A., Chingin K., Kozachenko A., Chen H., Frankevich V. Direct Mass Spectrometry Differentiation of Ectopic and Eutopic Endometrium in Patients with Endometriosis. Journal of Minimally Invasive Gynecology. 2018; 25(3): 426-33. DOI: 10.1016/ j.jmig.2017.08.658
  61. Dutta M., Joshi M., Srivastava S., Lodh I., Chakravarty B., Chaudhury K. A metabonomics approach as a means for identification of potential biomarkers for early diagnosis of endometriosis. Mol Biosyst. 2012; 8(12): 3281-7. doi: 10.1039/c2mb25353d
  62. Lee Y.H., Tan C.W., Venkatratnam A., Tan C.S., Cui L., Loh S.F., et al. Dysregulated sphingolipid metabolism in endometriosis, J. Clin Endocrinol Metab. 2014; 99(10): E1913-1921. doi: 10.1210/jc.2014-1340
  63. Chagovets V., Wang Z., Kononikhin A., Starodubtseva N., Borisova A., Salimova D., et al. Comparison of Tissue Spray and Lipid Extract Direct Injection Electrospray Ionization Mass Spectrometry for the Differentiation of Eutopic and Ectopic Endometrial Tissues. J. Am. Soc. Mass Spectrom. 2018; 29(2): 323-330. https://doi.org/10.1007/s13361-017-1792-y
  64. Chagovets V.V., Wang Z., Kononikhin A.S., Starodubtseva N.L., Borisova A., Salimova D., et al. Endometriosis foci differentiation by rapid lipid profiling using tissue spray ionization and high resolution mass spectrometry. Scientific Reports. 2017; 7(1), art. no. 2546. https://doi.org/10.1038/ s41598-017-02708-x

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2019

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies